Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

172
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
172
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

367
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
367
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

538
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
538
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

382
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
382
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

339
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
339
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

356
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
356

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of lay workers delivering behavioural activation for people with depression: systematic review and meta-analysis.

BJPsych open·2026
Same author

Healing Right Way: A Stepped Wedge Cluster Randomised Controlled Trial Aiming to Enhance Quality of Life for Aboriginal Australian Survivors of Stroke and Traumatic Brain Injury.

The Australian journal of rural health·2025
Same author

Knowledge + Innovation = Power: A protocol for implementing Aboriginal data sovereignty in an Aboriginal Medical Service for service delivery reform.

PloS one·2025
Same author

Representations of Clients and Speech and Language Therapists in Assessment Reports: A Critical Analysis.

International journal of language & communication disorders·2025
Same author

Effects of pre-operative continuing oral anticoagulants or antiplatelets on health outcomes among older patients with hip fracture: a systematic review and meta-analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Elizabeth Usher memorial lecture 2024: Speech-language pathology practice in Aboriginal spaces: A journey of learning and unlearning.

International journal of speech-language pathology·2025

Related Experiment Video

Updated: Apr 19, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K

Dosing algorithm revisit for busulfan following IV infusion.

Yanlin Wang1, Kazunobu Kato, Christopher Le Gallo

  • 1Otsuka Pharmaceutical Development and Commercialization, Inc., 506 Carnegie Center Drive, Princeton, NJ, 08540, USA.

Cancer Chemotherapy and Pharmacology
|January 7, 2015
PubMed
Summary

A new busulfan (Bu) dosing algorithm significantly improves drug exposure in hematopoietic stem cell transplantation (HSCT) patients. This optimized algorithm, based on body surface area (BSA), reduces under- or over-exposure compared to weight-based dosing.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

2.0K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

2.0K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.3K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Hematology

Background:

  • Busulfan (Bu) exposure is critical for efficacy and safety in hematopoietic stem cell transplantation (HSCT).
  • Current weight-based dosing (WBD) algorithms result in suboptimal Bu exposure, with a phase 2 study showing 33.6% of subjects under- or over-exposed.
  • Improving Bu dosing is essential to optimize treatment outcomes and minimize toxicity.

Purpose of the Study:

  • To investigate and develop an improved busulfan (Bu) dosing algorithm for hematopoietic stem cell transplantation (HSCT).
  • To enhance the accuracy of Bu exposure and reduce the incidence of under- or over-exposure.
  • To validate a simplified method for estimating Bu clearance (CL).

Main Methods:

  • Population pharmacokinetic (PK) modeling was performed using data from 207 patients.
  • A novel dosing algorithm was developed based on a covariate model for Bu clearance (CL), incorporating body surface area (BSA).
  • Model-based simulations were used to design a simplified test PK study with reduced sampling.

Main Results:

  • A one-compartment model adequately described Bu PK, with BSA being the best covariate for inter-individual variability in CL.
  • The proposed dosing algorithm is dose (mg) = (31.7 × BSA - 11.6) × target AUC [µM min]/1,000.
  • This new algorithm reduced under- or over-exposure to 14.3% of patients.
  • A shortened test PK study with three samples provided CL estimates comparable to 12 samples on two occasions.

Conclusions:

  • The developed busulfan (Bu) dosing algorithm significantly improves drug exposure in HSCT.
  • A simplified, shorter test PK study design with fewer samples is effective for estimating Bu clearance (CL).
  • The proposed simplified CL estimation method is valid and practical for clinical use.